Safety study of GIGA-2339 for chronic Hepatitis B
Part of Digestive system, Infections clinical trials.
This study tests an experimental antibody (GIGA-2339) given as an infusion to people with chronic Hepatitis B. It aims to see if the drug is safe and how the body processes it, possibly helping to control the virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic Hepatitis B (HBsAg positive) for at least 6 months and are HBeAg-negative.
- Your HBsAg level is between 100 and 2000 IU/mL.
- You are either on a stable antiviral therapy for at least 6 months or not on any antiviral treatment.
- You have a low viral load (HBV DNA ≤ 50 IU/mL if on antivirals, or ≤ 2000 IU/mL if not).
- You are not pregnant, breastfeeding, or able to become pregnant (or willing to use effective contraception).
- You do not have other liver infections (HIV, HCV, HDV), liver cirrhosis, or a history of certain heart conditions or recent cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
This trial tests a combination of three drugs (BRII-179, BRII-835, and PEG-IFNα) to see if they can better control chronic hepatitis B. It is for people who are already on antiviral therapy and have well-controlled virus levels.
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
This trial tests an experimental antibody treatment for people with chronic hepatitis B who have been on antiviral medication for at least 6 months. It aims to see if the antibody is safe and can help control the virus.
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
This study tests a new medicine called AHB-137 for people with chronic hepatitis B who are HBeAg negative and currently on antiviral therapy. The goal is to see if it can help control the virus better or allow you to stop your current medication safely.
Hear when a new Hepatitis B Virus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.